Navigation Links
AHF Criticizes Tibotec Over Steep Price for Newest AIDS Drug, Etravirine
Date:1/21/2008

Following FDA Approval, Company Announces $7,800 Wholesale Price for

Lifesaving Drug

LOS ANGELES, Jan. 21 /PRNewswire-USNewswire/ -- AIDS Healthcare Foundation (AHF) today urged Tibotec Pharmaceuticals Ltd., a division of Johnson & Johnson, to reconsider and reduce its steep price for its newest AIDS drug, etravirine (TMC 125), a non-nucleoside reverse transcriptase inhibitor, (NNRTI), which received Food and Drug Administration (FDA) approval on Friday after a fast track or 'priority review' and approval process granted to companies for medications and therapies intended to treat life-threatening illnesses such as AIDS. Immediately following FDA approval of the drug, which Tibotec will sell under the brand name Intelence, Reuters reported that the drug's wholesale cost will be $5.45 per tablet. At the approved dose of two tablets twice per day, a 30-day supply would be $654-or close to $8,000 per patient, per year (PPY) wholesale cost.

"We commend Tibotec for the development of this promising new HIV/AIDS drug, but strongly urge them to immediately reconsider and price this life- saving AIDS medicine more fairly," said Michael Weinstein, AIDS Healthcare Foundation President. "As with many AIDS drugs before it, the cost of Intelence will simply be out of the price range for most AIDS patients and threatens to further stress Medicaid and AIDS Drug Assistance Programs nationwide. Just last week, Governor Arnold Schwarzenegger announced plans to cut $7 million dollars from California's ADAP, a program that helps low-income Californians living with HIV/AIDS access such lifesaving drugs. AIDS drugs are priced at the maximum the market will bear, regardless of production costs. It appears Tibotec is once again following suit with the steep price of its newest AIDS drug."

Tibotec drew earlier criticism from AIDS advocates back in June 2006 after it received FDA approval for its Protease Inhibitor, Prezista (daruna
'/>"/>

SOURCE AIDS Healthcare Foundation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Kmart Lowers Flu Shot Price to $10
2. Trius Initiates U.S. Phase I Trial for its Oxazolidinone Antibacterial Drug, TR-701
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...lington Medical Resources (AMR), a,provider of pr...nd diagnostic,imaging industries, finds that over...n the U.S. during the third quarter of 2008. Privi...bulin (IVIG) and was launched in the first,quarte...d plasma of thousands,of donors and is used to tr...
(Date:11/18/2008)...f Influenza survey underscores that mothers need t... and Gold Medalist Kristi Yamaguchi joins initiati... While 78 percent of mothers in the United States ...hreatening disease that can strike anyone, only ha...ated this season, according to a new survey from t...
(Date:11/13/2008)...FirstCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a le...ium,diagnostics, medical imaging systems and surgi...eeds of women, today announced the results of the,... Cervista HPV high-risk,test is currently under re...launched in the European Union (EU) early in 2009....
(Date:11/13/2008)...s Cut Risk of Heart Attacks, Deaths, RESTON, Va.,... Disease,is the leading cause of death among Ameri...llions of dollars and causing untold suffering. No...ase - even among those who,weren,t thought to be a...eople could cut their risk of a,heart attack, stro...
Breaking Medicine Technology:Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Seniors Can Be Heartened by New Study on Statins 2Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 7665 1Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 7665 2Dads break bones of children more often than moms 7663 1Dads break bones of children more often than moms 7663 2FDA Panel Says No to Avastin for Advanced Breast Cancer 7661 1FDA Panel Says No to Avastin for Advanced Breast Cancer 7661 2FDA Panel Says No to Avastin for Advanced Breast Cancer 7661 3Scientists identify gene that influences alcohol consumption 7659 1Scientists identify gene that influences alcohol consumption 7659 2
...--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeu... portfolio of,apoptosis-triggering compounds will ...l poster presentations at next week,s 2007,Annual ...earch,(AACR), to be held in Los Angeles, Californi...een selected for presentation at the,"High Impact ...
...ITY, April 13, 2007 /PRNewswire-FirstCall/ - AEter...utical company,focused on endocrine therapy and on...bstracts outlining first in vitro data on its,PI3K...tagonist,JMR-132, which both may potentially prov...f cancer. These abstracts will be,presented at the...
Other Medicine Technology:Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 2Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 3Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 4Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 6AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 2AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 3
(Date:11/21/2008)...e/ -- In a statewide survey, 33 physicians credent...ry at Presbyterian Hospital of Dallas were honored..." Super Doctors ." , , Each year, the publi...l Media, Inc. to survey more than 38,000 medical p... you needed medical care, which doctor would you c...
(Date:11/21/2008)...1 A prestigious group of physician...ther in Williamsburg, VA on March 27-29, 2009 at t... information on cutting-edge therapeutic protocols...arch advances that impact patient care. The full p...nformation is available at www.bioconferences.com...
(Date:11/21/2008)...e/ -- Innerscope Research(TM), a revolutionary,bi...nal Response Measurement,announced today the app...he,company,s research and development, business s...hree appointments, who deliver a combined 60 years...nancial Officer and Vice President of,Strategy; D...
(Date:11/21/2008)...The University of Texas M. D. Anderson Cancer Cent...to eradicate breast cancer in Panama through the P...h of the Americas today at an event with Laura Bus... Fernndez de Torrijos, the First Lady of Panama. ...the U.S. Department of State and Susan G. Komen fo...
Breaking Medicine News(10 mins):Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...view that was published in the Friday’s issue of t... kids does not reduce their risk of fractures in t...of the maximum bone mass is got by the age of 18 y...ing bone mass at an early age might reduce the eff...
...to have developed a technique to find out if metas... liver.// <br.The research scientists at Wash...have developed a test for the prediction of whethe...r, where it could quickly transform into being ver...
... 'Raloxifene' can reduce postmenopausal women with...new study that has been published in the September... could protect postmenopausal women from developin... whether they are at high or low risk of developin...
...der, generation or income group, more and more peo...sus a gym and an exercise physiologist// at New Yo...center for sports medicine, thinks she knows why. ...t is safe, balanced, promotes fitness and importan...
Other Medicine News:Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3Health News:Dance Your Way to a Better Body 2Health News:Dance Your Way to a Better Body 3
...cal IOL is a foldable silicone IOL. It features a ...e inserted with The UNFOLDER® Silver-T Implant... first and only FDA-approved multifocal IOL, and t...nal visionnear, intermediate, and far. The ARRAY&r...
...ferred viscoelastic for phacoemulsification proced...rks from the start to the finish of the case. The ...lastic is the reason. The low to moderate vacuum f...nly a fraction of the viscoelastic agent. However,...
...scoelastic agent for the surgeon who performs cata... Amvisc possesses sufficient viscosity for excelle... is highly cohesive so that complete removal at th...ed. Amvisc is priced to compete with any sodium hy...
...onate (1.8%) viscoelastic solution combines maximu...flo maintains a deep anterior chamber and protects... ideal for routine cataract surgery but can be use...lastic. Combine all these properties with the conv...
Medicine Products: